{"id":45580,"date":"2014-10-13T15:53:19","date_gmt":"2014-10-13T19:53:19","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&#038;p=45580"},"modified":"2014-10-13T15:53:19","modified_gmt":"2014-10-13T19:53:19","slug":"selections-from-richard-lehmans-literature-review-october-13th","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2014\/10\/13\/selections-from-richard-lehmans-literature-review-october-13th\/","title":{"rendered":"Selections from Richard Lehman\u2019s Literature Review: October 13th"},"content":{"rendered":"<p><em>CardioExchange is pleased to reprint this selection from Dr. Richard Lehman\u2019s\u00a0<a href=\"http:\/\/blogs.bmj.com\/bmj\/category\/richard-lehmans-weekly-review-of-medical-journals\/\" target=\"_blank\">weekly journal review blog<\/a>\u00a0at\u00a0<a href=\"http:\/\/www.bmj.com\/\">BMJ.com<\/a>. Selected summaries are relevant to our audience, but we encourage members to engage with the\u00a0<a title=\"Lehman_8282012\" href=\"http:\/\/blogs.bmj.com\/bmj\/2014\/10\/13\/richard-lehmans-journal-review-13-october-2014\/\" target=\"_blank\">entire blog<\/a>.<\/em><\/p>\n<p><strong><em>Lancet<\/em> 11 October 2014 Vol 384<\/strong><\/p>\n<p><strong>Once-Weekly Dulaglutide vs. Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (pg.<\/strong> 1349): If I were Oscar Wilde, I would stretch my legs and declare, \u201cMy dear, if I have to read another of these trials I shall simply die of tedium.\u201d The object of despair is called: \u201c<a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2814%2960976-4\/abstract\">Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial<\/a>.\u201d Spending on type 2 diabetes in the UK is rising disproportionately, driven by incretin mimetic drugs with unknown long term effects. So here is a single blinded trial run by Eli Lilly to test its me-too contender. The language used is rather strange. \u201cAn independent external committee adjudicated deaths and non-fatal cardiovascular adverse events in a masked manner, with prespecified event criteria based on the preponderance of the evidence and clinical knowledge and experience.\u201d What does that actually mean? And if that is obscure, look at the conclusion, presented in statistic-wonkese: \u201cOnce-weekly dulaglutide is non-inferior to once-daily liraglutide for least-squares mean reduction in HbA1c, with a similar safety and tolerability profile.\u201d Delve deeper those who will: for my part I shall yawn and send for a good cigar, a glass of hock and seltzer, and a green carnation for my buttonhole.<\/p>\n<p><strong><em>The BMJ<\/em> 11 October 2014 Vol 349<\/strong><\/p>\n<p><strong>Variation in Patients\u2019 Perceptions of Elective Percutaneous Coronary Intervention in Stable Coronary Artery Disease:<\/strong> Speaking of informed choice before procedures, how many patients accurately perceive the benefits of elective percutaneous coronary intervention in stable coronary artery disease? I don\u2019t know the answer for British patients, but <a href=\"http:\/\/www.bmj.com\/content\/349\/bmj.g5309%20\">John Spertus and his team have tried to find out about Americans<\/a>. The answer, of course, is not very many: 90% thought that the procedure would extend life and 88% thought it would prevent a future heart attack. So much for the public understanding of evidence based medicine versus the vested interests of interventional cardiologists.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This week&#8217;s topics include a comparison of once-weekly dulaglutide and once-daily liraglutide in metformin-treated patients with type 2 diabetes and variation in patients&#8217; perceptions of elective PCI in stable CAD.<\/p>\n","protected":false},"author":475,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2377,2394,787,2395,301,2242,469],"class_list":["post-45580","post","type-post","status-publish","format-standard","hentry","category-general","tag-dulaglutide","tag-liraglutide","tag-metformin","tag-patient-perceptions","tag-pci","tag-stable-coronary-artery-disease","tag-type-2-diabetes"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/45580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/475"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=45580"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/45580\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=45580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=45580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=45580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}